πŸ‡ΊπŸ‡Έ FDA
Patent

US 11981741

Humanized anti-CD45 antibodies

granted A61KA61K51/1027A61K51/1069

Quick answer

US patent 11981741 (Humanized anti-CD45 antibodies) held by Actinium Phamaceuticals, Inc. expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Actinium Phamaceuticals, Inc.
Grant date
Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K51/1027, A61K51/1069, A61K51/1096